

CALL FOR PAPERS

Deadline for manuscript submission: 1 December 2026

This is a call for papers proposing articles for a supplement of the *Journal of the International AIDS Society* (JIAS), titled **"Expanding access to long-acting antiretroviral regimens: From implementation to real-world impact"**. It will be published in conjunction with IAS 2027, the 14th IAS Conference on HIV Science, which will take place in Geneva, Switzerland, in July 2027.

GUEST EDITORS:

Renee Heffron

University of Alabama at Birmingham
United States

Flavia Matovu Kiweewa

MU-JHU Research Collaboration
Uganda

Rayner Kay Jin Tan

National University of Singapore
Singapore

BACKGROUND

The advent of long-acting antiretroviral regimens is transforming the HIV prevention and treatment landscape. Over the past decade, multiple long-acting modalities for treatment and pre-exposure prophylaxis have advanced from early clinical development to market introduction, with varying administration routes. The introduction of these new prevention and treatment tools has expanded choice, with the potential to reduce dosing burden and improve long-term adherence across populations.

However, as the field progresses with newer long-acting regimens advancing through the pipeline, translating clinical success into population-level impact will require overcoming persistent barriers to access and uptake. These include drug prices and licensing constraints, regulatory and policy hurdles, and country-level operational challenges that are increasingly compounded by shifting geopolitical priorities and constrained funding.

As these products enter global markets, person-centred and context-adapted implementation – supported by sustained political commitment, coordinated action across health systems and partners, and community engagement – will be essential to ensure that long-acting options are acceptable, accessible and equitably delivered. In this context, JIAS is developing a supplement focusing on how long-acting HIV regimens can be implemented effectively and equitably to achieve real-world impact.

SUBMISSIONS

The scope of this call for papers is global and focuses on research highlighting current challenges and barriers to roll-out and uptake of long-acting antiretroviral regimens, along with lessons learnt and best practices from researchers, advocates and communities. The Editors will consider multiple article categories (Research, Short report, Review, Debate, Commentary, Viewpoint, Field Notes). We strongly encourage submissions from researchers in low- and middle-income countries and/or originating from community-academic partnerships, as well as papers focusing on priority populations, including adolescents, pregnant people, people who use drugs, and sexual and gender minorities.

Priority topics include:

1. Expanding access to and uptake of long-acting antiretrovirals for prevention and treatment, including regulatory, licensing and market-access pathways
2. Policy and regulatory considerations for priority populations

3. Financing, affordability and cost-effectiveness considerations for scale-up of long-acting antiretroviral regimens
4. Health system readiness and service delivery models, including differentiated delivery, task sharing and decentralized approaches (including pharmacy and community-led approaches)
5. Person-centred approaches to delivering long-acting regimens across a range of populations, including dynamic preferences, regimen switching and choice-based counselling
6. Implementation research highlighting strategies, mechanisms and best practices to address impediments in the delivery, scale-up and sustainment of long-acting antiretroviral regimens
7. Epidemiological reports of access and product choice across different countries and regions, and unmet needs
8. Research highlighting policy, regulatory, advocacy, epidemiological or implementation considerations for long-acting regimens in development, including oral, topical and injectable formulations
9. Real-world and long-term clinical impact
10. Research and perspectives that evaluate the role and impact of community-engaged approaches to the delivery, uptake and sustainment of long-acting antiretroviral regimens

SUBMISSION PROCESS

- Contributions should be emailed to supplement@jiasociety.org with the subject line, "JIAS supplement: Long-acting regimens", in the form of full manuscripts, written in English.
- Manuscripts must conform to the journal style and format for each manuscript category. Authors must adhere to basic specifications (including word counts), as stipulated in the [Author Guidelines](#).
- The article processing fees will be covered by the supplement sponsors (no charges for the authors).
- Authors can make initial enquiries by emailing supplement@jiasociety.org

MANUSCRIPT SELECTION PROCESS

- The Guest Editors will review initial submissions. Only manuscripts selected by the Guest Editors will be considered for inclusion in the supplement.
- Invitation and submission do not guarantee publication.
- Each selected manuscript will undergo editorial appraisal and peer review based on its individual merits.
- Only articles that are accepted after peer review will be published in the supplement; other manuscripts will be rejected.
- The journal holds supplements to the same standards as other issues. Specifically, all manuscripts under consideration for inclusion in a supplement must adhere to the journal's standards for overall quality, types of articles and types of content in the articles.

IMPORTANT DATES

1 December 2026: Manuscript submission closes

10 December 2026: Authors notified of the outcome of their manuscript submission

December 2026 – June 2027: Peer review process

5 July 2027: Publication and launch of the supplement